Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease?
J Transl Autoimmun 2022;
4:100124. [PMID:
35005591 PMCID:
PMC8716613 DOI:
10.1016/j.jtauto.2021.100124]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 09/20/2021] [Indexed: 11/22/2022] Open
Abstract
Takayasu arteritis and primary sclerosing cholangitis are two rare disorders. The pathogenesis of Takayasu arteritis involves immune-mediated mechanisms, and corticosteroids represent the mainstay for treatment. Conversely, the aetiology of primary sclerosing cholangitis remains elusive, even if dysimmunity seems to be one of the contributors to bile duct damage. Despite this, immunosuppressants do not alter disease course. In this paper we describe the association of these two rare disorders, with an unexpected normalization of cholestatic enzymes following steroid treatment. This might hint a novel subtype of sclerosing cholangitis with a prevalent immunebackground, or a local manifestation of Takayasu arteritis.
Unusual association of two rare entities: PSC (supported by the presence of IBD) and TA.
Onset of Takayasu after PSC diagnosis.
Lack of response to UDCA and fibrates.
Improvement of liver function tests after steroid treatment.
No changes on biliary tree reported on MRCP.
Collapse